Early research (Phase 1)Study completedNCT03801902
What this trial is testing
Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
Who this might be right for
Locally Advanced Lung Non-Small Cell CarcinomaLocally Recurrent Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8+2 more
National Cancer Institute (NCI) 26